Discover how Avigen’s avidity-based microfluidic platform resolved inconclusive cytotoxicity data for Etcembly’s novel tri-specific and bi-specific T cell engagers, delivering mechanism-of-action insights and a clear, rank-ordered comparison of cell engager performance against melanoma targets that standard endpoint assays could not provide. Download the full case study to learn how paired avidity and functional data enables confident, de-risked cell engager selection for immunotherapy development.